Our latest quiz highlights the role of bone marrow adiposity in patients with multiple myeloma.
C.High adult BMI
Obesity is the only known modifiable risk factor for multiple myeloma. According to a prospective analysis of data from three large cohort studies (the Nurse’s Health Study, the Health Professionals Follow-up Study, and the Women’s Health Study), high BMI in both early and late adulthood are risk factors for developing multiple myeloma.
D.All of the above
In recent years, researchers have identified roles of BMAT in multiple myeloma cell metabolism, inflammation, immune interaction, and effects on hypoxia and new blood cell vasculature. The endocrine activities of BMAT have been underappreciated until recently.
A.Adipocytes
BMAT was long assumed to be inactive structural support, triggered by declines in bone mineral mass. More recently, researchers have demonstrated that fat-storing adipocytes are actively involved in cancer cell activity in bone marrow.
B.Adipokines
BMAT adipocytes secrete leptin, adiponectin, resistin, adipsin, and visfatin. These adipokines play a healthy role in normal fat and energy metabolism; in obesity, however, secretion can become less well-regulated.
D.Osteoblast
Researchers at the University of Alabama at Birmingham have reported that aggressive myeloma cells shift osteoblast progenitors toward production of adipocytes. Bone marrow from patients with multiple myeloma contains more pre-adipocytes and larger adipocytes than bone marrow from healthy controls. The researchers found that both pre-adipocytes and mature adipocytes directly recruit multiple myeloma cells.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.